Article
Urology & Nephrology
Steven C. Campbell, Robert G. Uzzo, Jose A. Karam, Sam S. Chang, Peter E. Clark, Lesley Souter
Summary: The guideline focuses on active surveillance and follow-up after intervention for adult patients with clinically-localized renal masses suspicious for cancer. Recommendations include consideration of AS for solid enhancing tumors and complex cystic lesions. Follow-up should prioritize risk-based surveillance for local/systemic recurrences and potential treatment-related sequelae.
JOURNAL OF UROLOGY
(2021)
Review
Oncology
Jack Horan, Conor Reid, Michael R. Boland, Gordon R. Daly, Stephen Keelan, Angus J. Lloyd, Eithne Downey, Adam Walmsley, Marie Staunton, Colm Power, Abeeda Butt, Deirdre Duke, Arnold D. K. Hill
Summary: This study evaluated diagnostic modalities for recurrent breast cancer, with a focus on the role of annual clinical examination. The results showed that clinical examination provides little value in diagnosing recurrence, suggesting that surveillance programs should reduce focus on this modality and instead prioritize regular radiological assessment and ensuring easy access to breast clinics for patients with new symptoms/signs.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Paolo Zola, Giovannino Ciccone, Elisa Piovano, Luca Fuso, Daniela Di Cuonzo, Anna Castiglione, Eva Pagano, Elena Peirano, Fabio Landoni, Enrico Sartori, Fabrice Narducci, Oscar Bertetto, Annamaria Ferrero
Summary: The TOTEM study conducted a randomized trial on intensive versus minimalist follow-up regimens in endometrial cancer-treated patients. The study found that intensive follow-up did not improve overall survival rates, even in high-risk patients. Routine addition of vaginal cytology, laboratory, or imaging investigations is unnecessary according to the results of this trial.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
So-Youn Jung, Young Ae Kim, Dong-Eun Lee, Jungnam Joo, Joung Hwan Back, Sun-Young Kong, Eun Sook Lee
Summary: This study in Korea evaluated follow-up imaging after breast cancer surgery and found that frequent mammography reduced mortality, but frequent imaging with other modalities did not show the same effect. The findings support the importance of adhering to current guidelines for surveillance after breast cancer surgery.
Article
Urology & Nephrology
Steven C. Campbell, Peter E. Clark, Sam S. Chang, Jose A. Karam, Lesley Souter, Robert G. Uzzo
Summary: Significant progress has been made in the evaluation and management of clinically-localized renal masses. These guidelines offer updated, evidence-based recommendations on evaluation and counseling, highlighting the evolving role of renal-mass-biopsy (RMB).
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Qian Ouyang, Shunrong Li, Ming Gao, Liling Zhu, Shiyun Xu, Shunhao Meng, Siqiao Wu, Liqiu Huang, Fengxi Su, Zefang Ren, Kai Chen, Min Peng
Summary: The study identified several risk factors associated with post-operative loss to follow-up (LTFU) in breast cancer patients, including age, lack of medical insurance, distance from residence to hospital, pathology, lymph node metastasis, absence of endocrine therapy, and number of contact numbers. A LTFU-risk score was developed to predict LTFU and allows for individualized surveillance plans for patients with different risks.
Article
Oncology
Fernando A. Angarita, Nicole Jedrzejko, David Eisen, Maria Muraca, Marla Ash, Fahima Osman
Summary: This study investigated the perspective of primary care physicians (PCPs) in Toronto, Canada, regarding the barriers and needs associated with transitioning breast cancer follow-up care to their practices. The results revealed that PCPs require support in the form of follow-up care plans upon discharge, rapid re-referral to specialists, and regular updates of best practice changes. The majority of PCPs supported transitioning to a PCP-led model.
CLINICAL BREAST CANCER
(2022)
Article
Medicine, General & Internal
Lianlian Wu, Conghui Shi, Jia Li, Zehua Dong, Wei Zhou, Anning Yin, Yanxia Li, Yunchao Deng, Ming Xu, Shan Hu, Jie Pan, Yaowei Ai, Jun Liu, Yijie Zhu, Xiao Tao, Junxiao Wang, Hongliu Du, Xiaoquan Zeng, Honggang Yu
Summary: This study evaluated the accuracy of an automatic surveillance system in identifying patients after polypectomy and assigning surveillance intervals. The system was found to improve adherence to guidelines among physicians and reduce the workload among healthcare professionals.
Article
Radiology, Nuclear Medicine & Medical Imaging
Natasha Larocque, Olga R. Brook, Hadiseh Kavandi, James V. Rawson
Summary: The use of national guidelines for the management of incidental radiologic findings is low. Therefore, a study was conducted to improve adherence to and consistency with follow-up recommendations for incidental findings in a large academic practice. By using the Kotter change management framework and institution-specific dictation macros, improvements were made in the management of abdominal aneurysms. Personal feedback provided to radiologists further improved adherence and resulted in an increase in imaging follow-up.
Article
Medicine, General & Internal
Steven J. Atlas, Anna N. A. Tosteson, Timothy E. Burdick, Adam Wright, Erica S. Breslau, Tin H. Dang, Amy J. Wint, Rebecca E. Smith, Kimberly A. Harris, Li Zhou, Jennifer S. Haas
Summary: In this survey study of primary care practitioners, deficiencies in systems for managing abnormal cancer screening test results were reported, highlighting the need for comprehensive organ-agnostic systems to promote timely follow-up.
Article
Gastroenterology & Hepatology
Kofi Clarke, Kara DiJoseph, Rachel White, Ibrahim Yaghnam, Roland Lee, Jonathan G. Stine
Summary: This study evaluated adherence to post-polypectomy surveillance guidelines by academic gastroenterologists at a high-volume center. The results showed a greater than 85% adherence to the guidelines, regardless of the endoscopists' experience.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Article
Oncology
Emma C. Gertsen, Alicia S. Borggreve, Hylke J. F. Brenkman, Rob H. A. Verhoeven, Erik Vegt, Richard van Hillegersberg, Peter D. Siersema, Jelle P. Ruurda
Summary: The implementation of FDG-PET/CT and SL has increased in The Netherlands following the revision of guidelines, leading to longer waiting times for treatment despite not affecting the number of non-curative procedures performed.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Luis Sendra, Gladys G. Olivera, Rafael Lopez-Andujar, Cristina Serrano, Luis E. Rojas, Eva Maria Montalva, Maria Jose Herrero, Salvador F. Alino
Summary: This study analyzed the relationship between gene polymorphisms and the clinical outcomes of liver-transplanted patients. The results showed significant associations between certain gene variants and the risk of premature death, comorbidities, and drug sensitivity. These findings suggest the potential importance of pharmacogenetics in personalized drug prescription and clinical follow-up for liver-transplanted patients.
Article
Radiology, Nuclear Medicine & Medical Imaging
Yulia Lakhman, Hebert Alberto Vargas, Caroline Reinhold, Esma A. Akin, Priyadarshani R. Bhosale, Chenchan Huang, Stella K. Kang, Namita Khanna, Aoife Kilcoyne, Refky Nicola, Rajmohan Paspulati, Gaiane M. Rauch, Atul B. Shinagare, William Small, Phyllis Glanc
Summary: Vulvar cancer, an uncommon gynecologic tumor, is most commonly of squamous cell carcinoma subtype. Imaging is crucial for assessing tumor size, extent, and status of lymph nodes in diagnosis and management of vulvar cancer. The American College of Radiology Appropriateness Criteria provide evidence-based guidelines for imaging and treatment procedures in specific clinical scenarios.
JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Constantine A. Raptis, Alan Goldstein, Travis S. Henry, Kristin K. Porter, Daniel Catenacci, Aine Marie Kelly, Christopher T. Kuzniewski, Andrew R. Lai, Elizabeth Lee, Jason M. Long, Maria D. Martin, Michael F. Morris, Kim L. Sandler, Arlene Sirajuddin, Devaki Shilpa Surasi, Graham W. Wallace, Ihab R. Kamel, Edwin F. Donnelly
Summary: This document provides recommendations and guidelines for the role of imaging in the staging and follow-up of esophageal cancer. It suggests the use of esophagogastroduodenoscopy and esophageal ultrasound for initial clinical staging, and FDG-PET/CT or CT for evaluating distant nodal and metastatic disease. It also recommends the use of FDG-PET/CT during neoadjuvant chemotherapy and for assessing recurrence after treatment.
JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
(2022)
Article
Oncology
K. M. de Ligt, B. H. de Rooij, E. Hedayati, M. M. Karsten, V. R. Smaardijk, M. Velting, C. Saunders, L. Travado, F. Cardoso, E. Lopez, N. Carney, Y. Wengstrom, A. Ives, G. Velikova, M. D. L. Sousa Fialho, Y. Seidler, T. A. Stamm, L. B. Koppert, L. V. van de Poll-franse
Summary: For patients living with metastatic breast cancer (MBC), it is crucial to achieve the best possible health-related quality of life and maximize survival. However, there is currently no systematic way to determine if these goals are being achieved. A Core Outcome Set (COS) that allows standardized measurement of outcomes important to patients and promotes discussion of these outcomes during clinical encounters is urgently needed.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Olivia Pagani, Barbara A. Walley, Gini F. Fleming, Marco Colleoni, Istvan Lang, Henry L. Gomez, Carlo Tondini, Harold J. Burstein, Matthew P. Goetz, Eva M. Ciruelos, Vered Stearns, Herve R. Bonnefoi, Silvana Martino, Charles E. Geyer, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric P. Winer, Barbara Ruepp, Sherene Loi, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan, Prudence A. Francis
Summary: The combined analysis of SOFT-TEXT compared the outcomes of 4,690 premenopausal women with ER/PgR+ early breast cancer randomly assigned to exemestane + OFS or tamoxifen + OFS. Exemestane + OFS showed significant improvement in DFS and DRFI, but not overall survival, compared to tamoxifen + OFS. This study provides guidance for selecting patients who may benefit from exemestane over tamoxifen in the setting of OFS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar
Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Josephine M. N. L. Cardozo, Irene L. E. Andrulis, Stig E. Bojesen, Thilo M. Doerk, Diana M. A. Eccles, Peter A. J. Fasching, Maartje J. Hooning, Renske Keeman, Heli Nevanlinna, Emiel J. T. F. Rutgers, Douglas F. Easton, Per Hall, Paul D. P. J. Pharoah, Laura J. K. van't Veer, Marjanka K. Schmidt
Summary: A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer. The results showed that PRS313 is associated with favorable tumor characteristics but not independently associated with prognosis. Rating: 8/10.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frederique Penault-Llorca, Aleix Prat
Summary: Breast cancer multigene signatures (BCMS) have changed the management of early-stage breast cancer (eBC) by providing prognostic information and helping select patients for adjuvant chemotherapy. However, there is limited knowledge on the current usage and perceived utility of BCMS in clinical practice. A two-round Delphi survey involving 133 breast cancer experts from 11 European countries revealed that BCMS are widely used to assess risk of recurrence and select patients for adjuvant chemotherapy, but consensus is lacking regarding their utility in selecting specific chemotherapy types. There are also discrepancies between recommended usage and actual usage, with some profiles lacking supporting evidence. The study suggests the need for physician education initiatives to ensure proper use and interpretation of BCMS, ultimately improving management of eBC patients.
Article
Oncology
Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, Fatima Cardoso, Zeina Nahleh, Julie M. Vose, Julie R. Gralow, Michael Francisco, Shimere Sherwood
Summary: ASCO has taken steps to raise awareness about biosimilar products and published a statement in 2018 to provide guidance on their use in oncology. The FDA has approved a significant number of biosimilar products for use in the United States, including those for cancer treatment. The recent approval of interchangeable biosimilar products for various diseases has further expanded the market. This policy statement by ASCO proposes recommendations on value, interchangeability, clinician barriers, and patient education and access to guide their future activities.
JCO ONCOLOGY PRACTICE
(2023)
Article
Public, Environmental & Occupational Health
E. C. Karademas, I. Roziner, P. Simos, K. Mazzocco, R. Pat-Horenczyk, B. Sousa, A. J. Oliveira-Maia, G. Stamatakos, F. Cardoso, E. Kolokotroni, R. Lemos, C. Marzorati, J. Mattson, Pettini Greta, L. Travado, P. Poikonen-Saksela
Summary: This study aimed to investigate the changes in self-efficacy to cope with cancer over time in breast cancer patients and whether these changes were similar across patients. It also aimed to explore the relationship between these trajectories and patient psychological well-being and overall quality of life. A total of 404 participants from four countries were assessed a few weeks after breast surgery or biopsy. The majority of patients reported high levels of self-efficacy to cope, which increased over time. However, about 15% of patients experienced a decline in self-efficacy over time, which was associated with worse levels of well-being. The patterns of self-efficacy changes and their relationships with well-being were consistent across the countries.
PSYCHOLOGY & HEALTH
(2023)
Article
Medical Informatics
Mikko Nuutinen, Anna-Maria Hiltunen, Sonja Korhonen, Ira Haavisto, Paula Poikonen-Saksela, Johanna Mattson, Georgios Manikis, Haridimos Kondylakis, Panagiotis Simos, Ketti Mazzocco, Ruth Pat-Horenczyk, Berta Sousa, Fatima Cardoso, Isabel Manica, Ian Kudel, Riikka-Leena Leskela
Summary: This study aimed to examine whether machine learning can improve the prediction accuracy of clinicians in assessing breast cancer patients' quality of life. The results showed that incorporating machine learning into the clinical decision support system significantly enhanced clinicians' ability to predict patients' QoL.
HEALTH AND TECHNOLOGY
(2023)
Review
Oncology
Malwina Stanowicka-Grada, Elzbieta Senkus
Summary: Approximately 15-20% of breast cancers demonstrate HER2 overexpression/gene amplification. Anti-HER2 agents have significantly improved the prognosis and survival of patients with HER2-positive breast cancer. New anti-HER2 therapies have been developed, providing additional treatment options for advanced HER2-positive breast cancer. Current worldwide treatment options for metastatic breast cancer include different HER2 pathway blocking drugs at different stages. Clinical trials are ongoing to evaluate HER2 pathway blocking drugs in advanced disease settings. New data challenge current treatment standards, raising questions about the optimal sequence and combination of anti-HER2 targeted therapies, as well as treatment for special patient populations.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Fatima Cardoso, Amelia McCartney, Antonio Ponti, Lorenza Marotti, Conny Vrieling, Alexandru Eniu, Berta Sousa, Carla Ripamonti, Luzia Travado, Sabine Spitz, Eva Jolly, Giuseppe Curigliano, Frederique Penault-Llorca, Frederic Lecouvet, Isabel T. Rubio, Laura Biganzoli
Summary: The European Society of Breast Cancer Specialists and the Advanced Breast Cancer Global Alliance have developed the first set of quality indicators for metastatic breast cancer (MBC) with the aim of ensuring high-quality care and adherence to guidelines in breast cancer centers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Fatima Cardoso, Julie Rihani, Victoria Harmer, Nadia Harbeck, Ana Casas, Hope S. Rugo, Peter A. Fasching, Adam Moore, Joanna de Courcy, Purnima Pathak, Sina Haftchenary, Dawn Aubel, Eva Schumacher-Wulf
Summary: This article examines the perspectives of healthcare professionals and patients on quality of life (QOL) and the impact of treatment-related side effects on QOL. The study found discrepancies between healthcare professionals and patients regarding the importance of QOL discussions and the impact of side effects on QOL.
Article
Health Care Sciences & Services
Grazyna Suchodolska, Anna Koelmer, Monika Puchowska, Elzbieta Senkus
Summary: This study aims to explore the use of an in-app electronic questionnaire to assess and monitor chemotherapy-related symptoms in early breast cancer patients. The acceptance of the study was higher among younger women and patients from rural areas. However, the usage of the electronic questionnaire decreased substantially after the period of active encouragement during the study enrolment. The study concludes that patients' age should be carefully considered when introducing app-based interventions into usual cancer care and additional support is suggested for older patients to improve their awareness and participation in eHealth interventions.
Article
Oncology
Pedro F. Gouveia, Rogelio Luna, Francisco Fontes, David Pinto, Carlos Mavioso, Joao Anacleto, Rafaela Timoteo, Joao Santinha, Tiago Marques, Fatima Cardoso, Maria Joao Cardoso
Summary: Augmented reality (AR) has the potential to benefit the healthcare sector through real-time data acquisition, machine learning-aided processing, and visualization. This paper focuses on the future use of AR in breast surgery education, specifically surgical telementoring and impalpable breast cancer localization. The success of these applications depends on improvements in data transformation and infrastructures. (c) 2023 S. Karger AG, Basel
Article
Oncology
Hope S. S. Rugo, Victoria Harmer, Joyce O'Shaughnessy, Komal Jhaveri, Sara M. M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A. A. Fasching
Summary: This study compared patient-reported quality of life (QoL) between MONALEESA-2 (ribociclib + aromatase inhibitor) and MONARCH 3 (abemaciclib + aromatase inhibitor) treatments using a matching-adjusted indirect comparison (MAIC). The results showed that ribociclib + AI was associated with better symptom-related QoL compared to abemaciclib + AI.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Mark Lawler, Lynne Davis, Simon Oberst, Kathy Oliver, Alexander Eggermont, Anna Schmutz, Carlo La Vecchia, Claudia Allemani, Yolande Lievens, Peter Naredi, Tanja Cufer, Ajay Aggarwal, Matti Aapro, Kathi Apostolidis, Anne-Marie Baird, Fatima Cardoso, Andreas Charalambous, Michel P. Coleman, Alberto Costa, Mirjam Crul, Csaba L. Degi, Federica Di Nicolantonio, Sema Erdem, Marius Geanta, Jan Geissler, Jacek Jassem, Beata Jagielska, Bengt Jonsson, Daniel Kelly, Olaf Kelm, Teodora Kolarova, Tezer Kutluk, Grant Lewison, Francoise Meunier, Jana Pelouchova, Thierry Philip, Richard Price, Beate Rau, Isabel T. Rubio, Peter Selby, Maja Juznic Sotlar, Gilliosa Spurrier-Bernard, Jolanda C. van Hoeve, Eduard Vrdoljak, Willien Westerhuis, Urszula Wojciechowska, Richard Sullivan
Summary: Cancer research is vital for improving cancer care, and patients treated in research-active hospitals have better outcomes. However, the COVID-19 pandemic has negatively impacted cancer outcomes in Europe and set back progress by almost a decade. The Lancet Oncology European Groundshot Commission aims to use detailed data on cancer research to inform future cancer care strategies in Europe.